THROUGH ADVANCED DATA VISUALIZATION AND STREAMLINED DATA PROCESSING, RESEARCHERS ARE EMPOWERED TO NAVIGATE COMPLEXITIES SWIFTLY, FOSTERING INFORMED DECISIONS.
Since 2010, the average cost of launching new medicine has risen by 67%, with clinical trials accounting for two thirds of R&D costs alone. As a key industry player, Sanofi needed to incorporate new and individually tailored therapies into its trial protocols, while developing more flexible designs to address patients’ and sites’ needs. The company launched a dedicated program to make life easier for patients, investigators and their sponsors throughout the course of the trials.
Sanofi’s partnership with Capgemini aims to reduce the time required for developing new drugs by one to two years. Data visualization tools and accelerated data flow will also allow investigators to make better decisions, more quickly. Thanks to Capgemini’s technological expertise, Sanofi is able to collect and analyze big data to devise a new algorithm for patients and share it amongst different centers. It can also offer more flexible, personalized patient journeys with increased homecare options, thanks to a digital and integrated patient platform.
1-2 YEARS REDUCED DEVELOPMENT TIME
Thanks to a data-driven recruitment process, Sanofi has improved diversity in panels. And by improving the efficiency of its trials, they will reach their goal of bringing medicines to patients more quickly.
